Trial Profile
Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Simvastatin (Primary) ; Telmisartan (Primary)
- Indications Hypercholesterolaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 14 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 23 Jan 2008 The expected completion date for this trial is now 1 Aug 2007.
- 19 Dec 2007 Status changed from recruiting to in progress.